Abstract: Vaginal pharmaceutical compositions administrable through the topical route, particularly in the form of vaginal foams and creams containing a therapeutically effective amount of rifaximin (Common International Denomination) are useful in the treatment of vaginal infections, particularly bacterial vaginosis.

Abstract: Pharmaceutical formulations for oral administration coated by an enterosoluble gastroresistant film, preferably selected from gastroresistant granulates, gastroresistant tablets, gastroresistant hard gelatine capsules containing powders or granulates or two or more tablets or oily suspensions, gastroresistant soft gelatine capsules containing oily suspensions and hard gelatine capsules containing gastroresistant granulates or two or more gastroresistant tablets, containing therapeutically effective amounts of salts of bile acids with alkali metals or organic bases, process for their preparation and therapeutic use thereof in the treatment of biliary calculoses, biliary dyspepsias, biliary cirrhosis and chronic and cholestatic hepatopathies.

Abstract: Controlled release pharmaceutical formulations for oral administration coated by an enterosoluble gastroresistant film, preferably selected from gastroresistant granulates, gastroresistant tablets, gastroresistant hard gelatine capsules containing powders or granulates or two or more tablets or oily suspensions, gastroresistant soft gelatine capsules containing oily suspensions and hard gelatine capsules containing gastroresistant granulates or two or more gastroresistant tablets, containing therapeutically effective amounts of a mixture of bile acids and their salts with alkali metals or organic bases, process for their preparation and therapeutic use thereof in the treatment of biliary calculoses, biliary dyspepsias, biliary cirrhosis and chronic and cholestatic hepatopathies.

Abstract: The object of the present invention is the manufacture of a medicine for the use of glycosaminoglycans in the prevention and treatment of some pathologies caused by diabetes, like diabetic nephropathy and diabetic neuropathy.The effectiveness of glycosaminoglycans in the prevention and treatment of said pathologies has been shown by the treatment with some glycosaminoglycans of male albino rats made diabetic by treatment with streptozotocin or alloxan and by the subsequent determination of morphological and clinical parameters like the thickness of the glomerular basal membrane, the number of the glomerular anionic charges and albuminuria in case of diabetic nephropathy, and like the levels of substance P and Met-Enkephalin in some intestinal zones, like duodenum and jejunum, in case of diabetic neuropathy.

Abstract: Aqueous stable injectable formulations containing the sodium salt of naproxen, stabilizing agents and polyhydroxylic alcohols, packaged in containers made up of boxes of polystyrene or of an equivalent material covered with films which absorb the light radiations.

Abstract: Naphthalenes of formula ##STR1## wherein X represents COCH.sub.3, COC.sub.2 H.sub.5, CH(CH.sub.3)COOH, CH(CH.sub.3)COOR, CH(CH.sub.3)CN and CH(CH.sub.3)CONHR.sub.1, R represents alkyl and R.sub.1 represents hydrogen, alkyl or hydroxyalkyl, are debrominated by means of acceptors of bromine, like alkylarenes and alkoxyarenes, in the presence of Lewis acids.

Abstract: New heparinic derivatives having anticalculous activity, devoid of the anticoagulant and antithrombotic activity characteristic of the heparins, obtained by treating commercial or purified or low molecular weight heparins in a basic medium, optionally in the presence of alkali metal salts and of a reducing agent. The heparinic derivatives obtained through this treatment show significant chemical-physical characteristics, in particular they present a .sup.13 C-NMR spectrum different from that of the starting heparins especially in the zone between 102 and 92 p.p.m. with a characteristic signal at 101.3 p.p.m., a specific rotatory power at 546 nm between about +15.degree. and about +40.degree. in aqueous solution, a sulfur content between about 6% and about 9%, a sulfate/carboxyl ratio between about 1.20 and about 1.70 and a content of free amino groups between about 0.4% and about 2.1%. These heparin derivatives can be useful in the treatment of the nephrolithiases.

Abstract: Aqueous stable injectable formulations containing the sodium salt of naproxen, stabilizing agents and polyhydroxylic alcohols, packaged in containers made up of boxes of polystyrene or of an equivalent material covered with films which absorb the light radiations.

Abstract: New process for the synthesis of the .alpha.-(1-m.ethylethyl)-3,4-dimethoxyacetonitrile of formula (I): ##STR1## which is known as an intermediate in the synthesis of the drug internationally known as verapamil. The process starts from the isobutyryl-3,4-dimethoxybenzene of formula (II): ##STR2## which, by means of the Darzens condensation, gives an epoxyester which, by alkaline hydrolysis and subsequent decarboxylation, gives the .alpha.-(1-methylethyl)-3,4-dimethoxybenzeneacetaldehyde. This product is reacted with hydroxylamine to obtain the corresponding oxime that, by dehydration, gives the nitrile of formula I.

Abstract: New process for the synthesis of the N-methyl-3,4-dimetoxyphenylethylamine of formula ##STR1## intermediate in the synthesis of the drug internationally known as verapamil. The process starts from the 3,4-dimethoxybenzaldehyde which, by means of a Darzens condensation, gives an epoxyester that, by alkaline hydrolysis and subsequent decarboxylation, gives the 3,4-dimethoxyphenylacetaldehyde. This aldehyde gives the amine of formula I by reaction with monomethylamine followed by reduction with sodium borohydride.

Abstract: New galenic formulations with programmed release, to be administered by the oral route, containing as the active ingredient a drug selected from the non steroidal antiinflammatory, bronchodilator, vasodilator, cardiovascular and muscle relaxant drugs.

Abstract: A galenic formulations are disclosed with programmed release, to be administered orally containing as the active ingredient a compound having antiphlogistic, analgesic and antipyretic activity like, for instance, an arylacetic or an arylpropionic acid, and pharmaceutically acceptable salts thereof. In these new formulations, a portion of the active ingredient is released in a short time, so that the drug can quickly develop its therapeutic action and reach the necessary hematic levels, while the remaining portion of the active constituent is released in a longer interval of time so as to allow therapeutic coverage until subsequent administration. The therapeutic coverage can even last twenty-four hours. Thus, the new galenic formulations object of the present invention are suitable for administration one a day.